Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Number Needed to Treat Analyses of Zanubrutinib in Relapsed/Refractory Chronic Lymphocytic Leukaemia

Asher Alban Chanan-Khan, Kirollos S. Hanna, Mei Xue, Marjan Massoudi, Mark Balk, Hossein ZivariPiran, Cecilia Duan, Keri Yang

Blood (2023) 142 (Supplement 1): 2337.

https://doi.org/10.1182/blood-2023-174709

Published: 2023

Journal Articles

Genome-Wide DNA Methylation Analysis Reveals Epigenetic Influence on Intracellular and Cytokine Signaling Pathways in Waldenström Macroglobulinemia Compared to IgM-MGUS

Blood (2023) 142 (Supplement 1): 1622.

https://doi.org/10.1182/blood-2023-182874

Published: 2023

Journal Articles

Impact of Real-World Treatment Sequencing Patterns on Time to Next Treatment among Patients with Chronic Lymphocytic Leukemia in the United States

Asher Alban Chanan-Khan, Swetha Challagulla, Alpana Kaushiva, Vincent Miller, Yuexi Wang, Helen Smith, Keri Yang

Blood (2023) 142 (Supplement 1): 5143.

https://doi.org/10.1182/blood-2023-179536

Published: 2023

Journal Articles

Real-World Evaluation of Treatment Discontinuation and Healthcare Resource Utilization in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Asher Alban Chanan-Khan, Swetha Challagulla, Elizabeth Donckels, Po-Ya Chuang, Keri Yang

Blood (2023) 142 (Supplement 1): 5144.

https://doi.org/10.1182/blood-2023-179948

Published: 2023

Journal Articles

In Silico Modeling of Oncogenic Drivers in Waldenstrom Macroglobulinemia to Assess Additional Therapeutic Targets within the BCR Signaling Pathway Identifies MEK1/2 As a Target: Potential Therapeutic Role of Binimetinib

Aneel Paulus, MDMS, Sharoon Akhtar, MPhil, Shireen Vali, Ansu Kumar, Neeraj Kumar Singh, Shahabuddin Usmani, Himanshu Grover, Taher Abbasi, Asher Alban Chanan-Khan, MD

Blood (2015) 126 (23): 1279.

https://doi.org/10.1182/blood.V126.23.1279.1279

Published: 2015

Journal Articles

Identification of USP14 and UCHL5 As Druggable Oncotargets in Ibrutinib-Resistant Mantle Cell Lymphoma

Aneel Paulus, MDMS, Sharoon Akhtar, MPhil, Kelara Samuel, Hassan Yousaf, Davitte Cogen, Pooja Advani, MBBS, Thomas E. Witzig, MD, George J Weiner, MD, Sikander Ailawadhi, MD, Joachim Gullbo, MD PhD, Stig Linder, PhD, Geraldo Otero-Colon, Kasyapa S. Chitta, PhD, Asher Alban Chanan-Khan, MD

Blood (2015) 126 (23): 1557.

https://doi.org/10.1182/blood.V126.23.1557.1557

Published: 2015

Journal Articles

Phase I/II Clinical Trial of Lenalidomide in Combination with AT101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Aneel Paulus, MDMS, Pooja Advani, MBBS, Betsy R. Laplant, MS, Sharoon Akhtar, MPhil, Taimur Sher, MD, Candido E. Rivera, MD, James M. Foran, MD, Vivek Roy, MD, Gerardo Colon-Otero, MD, Sikander Ailawadhi, MD, Asher Alban Chanan-Khan, MD

Blood (2015) 126 (23): 5299.

https://doi.org/10.1182/blood.V126.23.5299.5299

Published: 2015

Journal Articles

Induction of Resistance to Proteasome Inhibition Preferentially Switches Survival Dependence from Bcl-2 to XIAP in Preclinical Models of Waldenstrom Macroglobulinemia: Pre-Clinical Rationale for Early Clinical Sequencing of ABT199

Sharoon Akhtar, MPhil, Aneel Paulus, MDMS, Kelara Samuel, Hassan Yousaf, Davitte Cogen, Vivek Roy, MD, Taimur Sher, MD, James M. Foran, MD, Candido E. Rivera, MD, Gerardo Colon-Otero, MD, Sikander Ailawadhi, MD, Asher Alban Chanan-Khan, MD

Blood (2015) 126 (23): 4839.

https://doi.org/10.1182/blood.V126.23.4839.4839

Published: 2015

Journal Articles

Aurora Kinase Is a Therapeutic Target in Ibrutinib-Resistant Waldenstrom Macroglobulinemia: In-Silico Target Identification and in-Vitro Validation

Aneel Paulus, MDMS, Kasyapa S. Chitta, PhD, Sharoon Akhtar, MPhil, Hassan Yousaf, Davitte Cogen, Shireen Vali, Ansu Kumar, Neeraj Kumar Singh, Taher Abbasi, James M. Foran, MD, Candido E. Rivera, MD, Taimur Sher, MD, Vivek Roy, MD, Sikander Ailawadhi, MD, Asher Alban Chanan-Khan, MD

Blood (2015) 126 (23): 2754.

https://doi.org/10.1182/blood.V126.23.2754.2754

Published: 2015

Journal Articles

VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia

Blood (2015) 126 (23): 703.

https://doi.org/10.1182/blood.V126.23.703.703

Published: 2015

Journal Articles

Appropriate Dose Adjustment of Dexamethasone Does Not Compromise Outcomes in Relapsed Refractory Multiple Myeloma

Abhisek Swaika, MBBS, Vivek Roy, MD, Zhuo Li, M.S, Neha Sood, MD, Kristina Laumann, Amanda Shreders, MD, Joseph Mikhael, MD, Shaji Kumar, MD, Asher Alban Chanan-Khan, MD, Martha Q. Lacy, MD, Sikander Ailawadhi, MD

Blood (2015) 126 (23): 1839.

https://doi.org/10.1182/blood.V126.23.1839.1839

Published: 2015

Journal Articles

Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial

P. Leif Bergsagel, MD, Martha Q. Lacy, MD, David Dingli, MD PhD, Shaji K. Kumar, MD, Sikander Ailawadhi, MD, Angela Dispenzieri, MD, Francis Buadi, MD, Morie A. Gertz, MD, A. Keith Stewart, MD, Craig B. Reeder, MD, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, Yi Lin, MD PhD, Asher Alban Chanan-Khan, MD, Marta Chesi, PhD

Blood (2015) 126 (23): 3039.

https://doi.org/10.1182/blood.V126.23.3039.3039

Published: 2015

Journal Articles

Outcome Disparities in T-Cell Non-Hodgkin Lymphoma and the Lack of Significant Improvement over the Years: A SEER Database Review

Jennifer A Crozier, MD, Taimur Sher, MD, Dongyun Yang, PhD, Abhisek Swaika, MBBS, James M. Foran, MD, Han W Tun, MD, Gerardo Colon-Otero, MD, Asher Alban Chanan-Khan, MD, Sikander Ailawadhi, MD

Blood (2014) 124 (21): 2597.

https://doi.org/10.1182/blood.V124.21.2597.2597

Published: 2014

Journal Articles

MYD88 Pathway Activation in Lymphoplasmacytic Lymphoma Drives Tumor Cell Growth and Cytokine Expression.

Stephen M Ansell, M.D., Ph.D., Frank J Secreto, Ph.D., Michelle Manske, Esteban Braggio, Ph.D., Lucy S. Hodge, PharmD, Ph.D., Tammy Price-Troska, Steven C. Ziesmer, Asher Alban Chanan-Khan, M.D., Morie A Gertz, M.D., Ahmet Dogan, MD, PhD, James R Cerhan, MD, PhD, Anne J Novak, Ph.D.

Blood (2012) 120 (21): 2699.

https://doi.org/10.1182/blood.V120.21.2699.2699

Published: 2012

Journal Articles

Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study

Blood (2011) 118 (21): 1875.

https://doi.org/10.1182/blood.V118.21.1875.1875

Published: 2011

Journal Articles

At-101 Induces Apoptosis Waldenström Macroglobulinemia Cells Resistant to Bortezomib.

Kasyapa Chitta, Ph.D., Kiersten M. Miles, Pushpankur Ghoshal, PhD, Leighton Stein, Morton Coleman, MD, Richard R Furman, MD, Hofmeister Craig, MD, Suzanne Hayman, Kelvin P. Lee, MD, Asher Alban Chanan-Khan

Blood (2009) 114 (22): 2861.

https://doi.org/10.1182/blood.V114.22.2861.2861

Published: 2009

Journal Articles

Novel Agents Overcome the Adverse Prognosis Imparted by Compromised Renal Function in Patients with Multiple Myeloma

Mehul Patel, Taimur Sher, Sikander Ailawadhi, Terry Mashtare, Jr., Wei Tan, Pranay Soni, Gregory Wilding, Kena C Miller, Alice Mohr, Kelvin P. Lee, Asher Alban Chanan-Khan

Blood (2008) 112 (11): 2726.

https://doi.org/10.1182/blood.V112.11.2726.2726

Published: 2008

Journal Articles

Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma

Paul Richardson, MD, Craig C. Hofmeister, MD, Todd M. Zimmerman, MD, Asher Alban Chanan-Khan, MD, Matthew A. Spear, MD, Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Gillian Cropp, MS, G. Kenneth Lloyd, PhD, Sandra Wear, Alison L. Hannah, MD, Kenneth C Anderson, MD

Blood (2008) 112 (11): 2770.

https://doi.org/10.1182/blood.V112.11.2770.2770

Published: 2008

Journal Articles

A Humanized Anti-Ganglioside GM2 Antibody, BIW-8962, Exhibits ADCC/CDC Activity against Multiple Myeloma Cells and Potent Anti- Tumor Activity in Mouse Xenograft Models.

Toshihiko Ishii, Asher Alban Chanan-Khan, MD, Jazur Jafferjee, MD, Noreen Ersing, Takeshi Takahashi, PhD, Masato Mizutani, PhD, Yukimasa Shiotsu, PhD, Nobuo Hanai, PhD

Blood (2008) 112 (11): 1718.

https://doi.org/10.1182/blood.V112.11.1718.1718

Published: 2008

Journal Articles

Results of a Phase I Study of GRN163L, a Direct Inhibitor of Telomerase, in Patients with Relapsed and Refractory Multiple Myeloma (MM)

Asher Alban Chanan-Khan, MD, Nikhil C. Munshi, MD, Mohamad A. Hussein, M.D., Laurence Elias, MD, Fabio Benedetti, M.D., Jennifer Smith, Ph.D., Soo-Peang Khor, Ph.D., Carol A. Huff, MD

Blood (2008) 112 (11): 3688.

https://doi.org/10.1182/blood.V112.11.3688.3688

Published: 2008

NARROW

Number Needed to Treat Analyses of Zanubrutinib in Relapsed/Refractory Chronic Lymphocytic Leukaemia

Genome-Wide DNA Methylation Analysis Reveals Epigenetic Influence on Intracellular and Cytokine Signaling Pathways in Waldenström Macroglobulinemia Compared to IgM-MGUS

Impact of Real-World Treatment Sequencing Patterns on Time to Next Treatment among Patients with Chronic Lymphocytic Leukemia in the United States

Real-World Evaluation of Treatment Discontinuation and Healthcare Resource Utilization in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

In Silico Modeling of Oncogenic Drivers in Waldenstrom Macroglobulinemia to Assess Additional Therapeutic Targets within the BCR Signaling Pathway Identifies MEK1/2 As a Target: Potential Therapeutic Role of Binimetinib

Identification of USP14 and UCHL5 As Druggable Oncotargets in Ibrutinib-Resistant Mantle Cell Lymphoma

Phase I/II Clinical Trial of Lenalidomide in Combination with AT101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Induction of Resistance to Proteasome Inhibition Preferentially Switches Survival Dependence from Bcl-2 to XIAP in Preclinical Models of Waldenstrom Macroglobulinemia: Pre-Clinical Rationale for Early Clinical Sequencing of ABT199

Aurora Kinase Is a Therapeutic Target in Ibrutinib-Resistant Waldenstrom Macroglobulinemia: In-Silico Target Identification and in-Vitro Validation

VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia

Appropriate Dose Adjustment of Dexamethasone Does Not Compromise Outcomes in Relapsed Refractory Multiple Myeloma

Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial

Outcome Disparities in T-Cell Non-Hodgkin Lymphoma and the Lack of Significant Improvement over the Years: A SEER Database Review

MYD88 Pathway Activation in Lymphoplasmacytic Lymphoma Drives Tumor Cell Growth and Cytokine Expression.

Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study

At-101 Induces Apoptosis Waldenström Macroglobulinemia Cells Resistant to Bortezomib.

Novel Agents Overcome the Adverse Prognosis Imparted by Compromised Renal Function in Patients with Multiple Myeloma

Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma

A Humanized Anti-Ganglioside GM2 Antibody, BIW-8962, Exhibits ADCC/CDC Activity against Multiple Myeloma Cells and Potent Anti- Tumor Activity in Mouse Xenograft Models.

Results of a Phase I Study of GRN163L, a Direct Inhibitor of Telomerase, in Patients with Relapsed and Refractory Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only